Related Experiment Video

Updated: Dec 19, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Landscape of drug-resistance mutations in kinase regulatory hotspots

Pora Kim, Hanyang Li, Junmei Wang

    Briefings in Bioinformatics
    |June 9, 2020
    PubMed

    Insights

    Drug resistance in cancer therapy is a major challenge. This study maps kinase mutations linked to drug resistance, aiding the development of next-generation kinase inhibitors for precision medicine.

    Area of Science:

    • Biochemistry
    • Genomics
    • Pharmacology

    Background:

    • Over 48 kinase inhibitors (KIs) are FDA-approved, but drug resistance (DR) remains a significant clinical challenge.
    • Secondary mutations in cancer cells frequently drive acquired resistance to targeted therapies.
    • Understanding kinase domain (KD) mutations is crucial for treating kinasopathies and overcoming resistance.

    Purpose of the Study:

    • To systematically investigate kinase mutations at drug resistance hotspots across 538 human protein kinases.
    • To create a comprehensive landscape of mutations associated with acquired drug resistance.
    • To provide foundational knowledge for developing next-generation kinase inhibitors.

    Main Methods:

    • Utilized large-scale cancer datasets (TCGA, ICGC, COSMIC, GDSC) to analyze mutations.
    • Focused on four key mutation hotspots: gatekeeper, G-loop, αC-helix, and A-loop.
    • Performed computational assessment and validation of specific mutations, such as those in epidermal growth factor receptor (EGFR).

    Main Results:

    • Identified 358 kinases with 3318 mutations affecting 702 drug resistance hotspot residues.
    • Found that 197 kinases exhibited multiple genetic variants at individual hotspot residues.
    • Demonstrated EGFR mutation analysis on protein structure and drug-binding efficacy.

    Conclusions:

    • This study presents the first landscape view of drug resistance-associated mutation hotspots in kinase secondary structures.
    • The findings highlight the complexity of kinase mutations driving drug resistance.
    • This knowledge is vital for designing effective next-generation kinase inhibitors and advancing precision medicine.
    Keywords:
    A-loopG-loopgatekeeperkinase inhibitormutation hotspotαC-helix

    More Related Videos

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

    Published on: October 23, 2019

    8.2K
    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

    Published on: December 9, 2015

    11.0K

    Related Concept Videos

    Interactions Between Signaling Pathways01:19

    Interactions Between Signaling Pathways

    Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
    Convergence and divergence, and cross-talk between signaling pathways
    Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
    7.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.6K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.5K
    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    7.6K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    5.1K
    Amplifying Signals via Enzymatic Cascade01:22

    Amplifying Signals via Enzymatic Cascade

    When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
    16.7K